Drugs / Toludesvenlafaxine
Toludesvenlafaxine
also known as
LY03005 · Toludesvenlafaxine hydrochloride · ansofaxine · LPM-570065 · LPM-570065 FREE BASE · LY-03005 HYDROCHLORIDE DIHYDRATE · ODVP2 · ODVP2 HYDROCHLORIDE DIHYDRATE · +2 more
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT03822065 | Jan → Feb 2019 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03733574 | Jun → Jul 2018 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03357796 | Nov → Dec 2017 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02988024 | Dec 2016 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03785652 | Oct 2015 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02271412 | Oct 2014 → Mar 2015 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02055300 | Feb → Aug 2014 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05970510 | Aug 2023 → Jul 2025 | generalized anxiety disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04853407 | Dec 2018 → Dec 2020 | major depressive disorder | Luye Pharma Group Ltd. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07552246 | Apr 2026 → Mar 2027 expected | mixed anxiety and depressive disorder | Duke Kunshan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06426485 | May 2024 → Feb 2027 expected | major depressive disorder | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06026917 | Sep 2023 → Jan 2024 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT05849272 | May 2023 → May 2024 | somatoform disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07709416 | Sep 2026 → Sep 2028 expected | — | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07208357 | Oct 2025 → Jun 2027 expected | fibromyalgia | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT06278038 | Feb → Nov 2024 | major depressive disorder | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| — | NCT06270433 | Feb → Dec 2024 | atypical depressive disorder | Jiangsu Province Nanjing Brain Hospital | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Toludesvenlafaxine | “Administer Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.” NCT07552246 ↗ |
| Known as | ansofaxine | “A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.” PMID 37164957 ↗ May 2023 |
| Known as | LPM-570065 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | LPM-570065 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | LY-03005 HYDROCHLORIDE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | LY03005 | “A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.” PMID 37164957 ↗ May 2023 |
| Known as | ODVP2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | ODVP2 HYDROCHLORIDE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | Roxylin | “OBJECTIVE: This study aimed to evaluate the efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets (Roxylin®) for somatic symptoms of major...” PMID 40661857 ↗ Jul 2025 |
| Known as | Toludesvenlafaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4227736 ↗ |
| Known as | Toludesvenlafaxine hydrochloride | “Toludesvenlafaxine hydrochloride sustained-release tablets” NCT06270433 ↗1“Toludesvenlafaxine Hydrochloride Sustained-release Tablets” NCT06426485 ↗ |
| Action | Inhibit | “a potential triple reuptake inhibitor of serotonin, norepinephrine, and dopamine” PMID 37164957 ↗ May 2023 |
| Modality | Small molecule | — CHEMBL4227736 ↗ |
| Route | Oral | “single oral doses of LY03005” NCT02055300 ↗ |